MET and cancer: In HepG2 cells, LZ8 suppressed HGF-induced c-Met signaling (p-c-Met, p-JNK, p-ERK, and p-paxillin) and cancer cell migration at concentrations of 25–100 μg/mL, outperforming JNJ-38877605 (a c-Met-specific antagonist).